Skip to main content
SpringerLink
Log in

Thiopurines in inflammatory bowel disease: New strategies for optimization of pharmacotherapy?

  • Invited Commentary
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Conclusions

New strategies for optimizing thiopurine therapy of IBD are promising. TDM and TPMT genotyping seem to be important tools for fine tuning thiopurine therapy, thereby reducing toxicity and improving efficacy. ITPA genotyping and the use of 6-TG in IBD need further research before they can be advocated or banned.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adler DJ, Korelitz BI: The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990, 85:717–722.

    PubMed  CAS  Google Scholar 

  2. Pearson DC, May GR, Fick GH, et al.: Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med 1995, 123:132–142.

    PubMed  CAS  Google Scholar 

  3. Sandborn WJ: A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996, 91:423–433.

    PubMed  CAS  Google Scholar 

  4. Kirschner BS: Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998, 115:813–821.

    Article  PubMed  CAS  Google Scholar 

  5. Present DH, Meltzer SJ, Krumholz MP, et al.: 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989, 111:641–649.

    PubMed  CAS  Google Scholar 

  6. Connell WR, Kamm MA, Ritchie JK, et al.: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993, 34:1081–1085.

    PubMed  CAS  Google Scholar 

  7. Lennard L, Singleton HJ: High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992, 583:83–90.

    Article  PubMed  CAS  Google Scholar 

  8. Dervieux T, Boulieu R: Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998, 44:551–555.

    PubMed  CAS  Google Scholar 

  9. Erdmann GR, France LA, Bostrom BC, et al.: A reversed phase high performance liquid chromatography approach in determining total red blood cell concentrations of 6-thioguanine, 6-mercaptopurine, methylthioguanine, and methylmercaptopurine in a patient receiving thiopurine therapy. Biomed Chromatogr 1990, 4:47–51.

    Article  PubMed  CAS  Google Scholar 

  10. Cuffari C, Theoret Y, Latour S, et al.: 6-Mercaptopurine metabolism in Crohn’s disease: correlation with efficacy and toxicity. Gut 1996, 39:401–406.

    PubMed  CAS  Google Scholar 

  11. Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705–713.

    Article  PubMed  CAS  Google Scholar 

  12. Cuffari C, Hunt S, Bayless T: Utilisation of erythrocyte 6- thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001, 48:642–646.

    Article  PubMed  CAS  Google Scholar 

  13. Achkar JP, Stevens T, Easley K, et al.: Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:339–345.

    Article  PubMed  Google Scholar 

  14. Hindorf U, Lyrenas E, Nilsson A, et al.: Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol 2004, 39:1105–1112.

    Article  PubMed  CAS  Google Scholar 

  15. Dubinsky MC, Yang H, Hassard PV, et al.: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122:904–915.

    Article  PubMed  CAS  Google Scholar 

  16. Belaiche J, Desager JP, Horsmans Y, et al.: Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001, 36:71–76.

    Article  PubMed  CAS  Google Scholar 

  17. Lowry PW, Franklin CL, Weaver AL, et al.: Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001, 49:665–670.

    Article  PubMed  CAS  Google Scholar 

  18. Gupta P, Gokhale R, Kirschner BS: 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001, 33:450–454.

    Article  PubMed  CAS  Google Scholar 

  19. Goldenberg BA, Rawsthorne P, Bernstein CN: The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004, 99:1744–1748.

    Article  PubMed  CAS  Google Scholar 

  20. Sandborn WJ: 6-MP metabolite levels: a potential guide to Crohn’s disease therapy. Gastroenterology 1997, 113:690–692.

    Article  PubMed  CAS  Google Scholar 

  21. Cohen RD: Forecast for using metabolite measurements in the dosing of azathioprine or 6-mercaptopurine for IBD patients: "partly cloudy". Gastroenterology 2002, 122:2082–2084, discussion 2084.

    PubMed  Google Scholar 

  22. Derijks LJ, Gilissen LP, Engels LG, et al.: Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 2004, 26:311–318.

    Article  PubMed  CAS  Google Scholar 

  23. Gilissen LP, Derijks LJ, Bos LP, et al.: Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2004, 16:705–710.

    Article  PubMed  CAS  Google Scholar 

  24. Gilissen LP, Derijks LJJ, Bos LP, et al.: Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy. Clin Drug Invest 2004, 24:479–486.

    Article  CAS  Google Scholar 

  25. Ansari A, Hassan C, Duley J, et al.: Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16:1743–1750.

    Article  PubMed  CAS  Google Scholar 

  26. Black AJ, McLeod HL, Capell HA: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998, 129:716–718.

    PubMed  CAS  Google Scholar 

  27. Lennard L: TPMT in the treatment of Crohn’s disease with azathioprine. Gut 2002, 51:143–146.

    Article  PubMed  CAS  Google Scholar 

  28. Louis E, Belaiche J: Optimizing treatment with thioguanine derivatives in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2003, 17:37–46.

    Article  PubMed  CAS  Google Scholar 

  29. Colombel JF, Ferrari N, Debuysere H, et al.: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000, 118:1025–1030.

    Article  PubMed  CAS  Google Scholar 

  30. Marinaki AM, Ansari A, Duley JA, et al.: Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004, 14:181–187.

    Article  PubMed  CAS  Google Scholar 

  31. Gearry RB, Roberts RL, Barclay ML, et al.: Lack of association between the ITPA 94C< A polymorphism and adverse effects from azathioprine. Pharmacogenetics 2004, 14:779–781.

    Article  PubMed  CAS  Google Scholar 

  32. Allorge D, Hamdan R, Broly F, et al.: ITPA genotyping test does not improve detection of Crohn’s disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut 2005, 54:565.

    Article  PubMed  CAS  Google Scholar 

  33. Dubinsky MC, Hassard PV, Seidman EG, et al.: An openlabel pilot study using thioguanine as a therapeutic alternative in Crohn’s disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001, 7:181–189.

    Article  PubMed  CAS  Google Scholar 

  34. Baert F, Rutgeerts P: 6-Thioguanine: a naked bullet? (Or how pharmacogenomics can make old drugs brand new). Inflamm Bowel Dis 2001, 7:190–191.

    Article  PubMed  CAS  Google Scholar 

  35. Derijks LJ, De Jong DJ, Gilissen LP, et al.: 6-Thioguanine seems promising in azathioprineor 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 2003, 15:63–67.

    Article  PubMed  CAS  Google Scholar 

  36. Dubinsky MC, Feldman EJ, Abreu MT, et al.: Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003, 98:1058–1063.

    Article  PubMed  CAS  Google Scholar 

  37. Bonaz B, Boitard J, Marteau P, et al.: Tioguanine in patients with Crohn’s disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2003, 18:401–408.

    Article  PubMed  CAS  Google Scholar 

  38. Lancaster DL, Patel N, Lennard L, et al.: Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 2002, 50:33–36.

    Article  PubMed  CAS  Google Scholar 

  39. Dervieux T, Blanco JG, Krynetski EY, et al.: Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001, 61:5810–5816.

    PubMed  CAS  Google Scholar 

  40. Herrlinger KR, Kreisel W, Schwab M, et al.: 6-thioguanine-efficacy and safety in chronic active Crohn’s disease. Aliment Pharmacol Ther 2003, 17:503–508.

    Article  PubMed  CAS  Google Scholar 

  41. Herrlinger KR, Deibert P, Schwab M, et al.: Remission maintenance by tioguanine in chronic active Crohn’s disease. Aliment Pharmacol Ther 2003, 17:1459–1464.

    Article  PubMed  CAS  Google Scholar 

  42. Dubinsky MC, Vasiliauskas EA, Singh H, et al.: 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003, 125:298–303.

    Article  PubMed  CAS  Google Scholar 

  43. Geller SA, Dubinsky MC, Poordad FF, et al.: Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol 2004, 28:1204–1211.

    Article  PubMed  Google Scholar 

  44. Naber AH, Van Haelst U, Yap SH: Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients. J Hepatol 1991, 12:94–99.

    Article  PubMed  CAS  Google Scholar 

  45. Stromeyer FW, Ishak KG: Nodular transformation (nodular "regenerative "hyperplasia) of the liver: a clinicopathologic study of 30 cases. Hum Pathol 1981, 12:60–71.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy, Máxima Medical Center, PO Box 7777, 5500, MB Veldhoven, The Netherlands

    Luc J. J. Derijks PharmD

Authors
  1. Luc J. J. Derijks PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel W. Hommes MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luc J. J. Derijks PharmD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Derijks, L.J.J., Hommes, D.W. Thiopurines in inflammatory bowel disease: New strategies for optimization of pharmacotherapy?. Curr Gastroenterol Rep 8, 89–92 (2006). https://doi.org/10.1007/s11894-006-0001-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-006-0001-0

Keywords

Search

Navigation